Small Molecules, Big Promises: Improvement of Psoriasis Severity and Glucidic Markers with Apremilast: A Case Report
Caterina Lanna,* Gaia Maria Cesaroni,* Sara Mazzilli, Luca Bianchi, Elena Campione Dermatologic Unit, University of Rome Tor Vergata, Rome, Italy*These authors contributed equally to this workCorrespondence: Caterina LannaDermatologic Unit, Department of Systems Medicine, University of Rome Tor Verg...
Guardado en:
Autores principales: | Lanna C, Cesaroni GM, Mazzilli S, Bianchi L, Campione E |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/68e9d06333ca45658b0367822abe8b4a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Phosphodiesterase-4 Inhibition in Psoriasis
por: Milakovic M, et al.
Publicado: (2021) -
Psoriasis In Patients With Active Lung Cancer: Is Apremilast a Safe Option?
por: Zoe Apalla, et al.
Publicado: (2019) -
The Use of Apremilast in Psoriasis: An Indian Perspective on Real-World Scenarios
por: Rajagopalan M, et al.
Publicado: (2021) -
The Effect of TNF-α Inhibitors on Nail Psoriasis and Psoriatic Arthritis—Real-World Data from Dermatology Practice
por: Georgios Kokolakis, et al.
Publicado: (2021) -
Psoriasis
por: MOLL LEE,NORMAN
Publicado: (1947)